Navigation Links
Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company

BEVERLY, Mass., March 8, 2011 /PRNewswire/ -- Cellceutix Corporation (Pink Sheets: CTIX) today disclosed that it has entered into a Confidential Disclosure Agreement (CDA) pertaining to its anti-cancer drug, Kevetrin™, with one of the world's largest pharmaceutical companies.

Cellceutix CEO, Leo Ehrlich, commented, "It's relatively uncommon for big pharma to be signing a CDA on a compound before clinical trials are underway.  The process begins with Cellceutix providing non-confidential information to the other party.  If after review of the materials the interest remains high, they will request to enter into a CDA.   We are glad that their interpretation of the Kevetrin™ studies was sufficient to warrant entering into a CDA with Cellceutix."  Mr. Ehrlich continued, "Signing a CDA does not mean a licensing deal or other transaction is imminent and makes no assumptions that it ever will.  But, conversely, a deal won't ever happen without first signing a CDA.  At Cellceutix, we are focused on moving our compounds toward clinical trials and maximizing shareholders' value.  This agreement is one more step in that process."

Cellceutix has previously reported that in animal studies Kevetrin™ has shown potent anti-tumor activity against many different cancers including lung, breast and colon cancers as well as leukemia and various strains for which current drugs are ineffective ("drug-resistant cancers").  Data released over the last week by Cellceutix has also shown that Kevetrin™ demonstrates characteristics that are seen as highly desirable in a new chemotherapy as it has not only shown to be non-genotoxic, but also reactivates p53, the "Guardian Angel Protein."    

About Cellceutix

Cellceutix Corporation is a preclinical cancer, anti-inflammatory and autism drug developer.  Cellceutix owns the rights to eight drug compounds, including Kevetrin, which it is developing as a treatment for certain cancers, KM-133, for the treatment of psoriasis, and KM-391, for the treatment of autism.  More information is available on the Cellceutix web site at

Kevetrin, KM133, and KM-391 have not been studied in humans at this time. The Company's positive results in animal studies do not necessarily guarantee success in humans, though they may form the basis for beginning Phase 1 trials.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by Cellceutix Corporation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.

SOURCE Cellceutix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cellceutix Discovers Drug Activates Guardian Angel p53 in Fight Against Leukemia
2. Cellceutix Cancer Drug Kevetrin™ Shows No Genotoxicity in Study
3. Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results
4. Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
5. RBC Life Sciences Reports Sales and Earnings Growth in 2010
6. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results
7. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
8. IRIDEX Reports Strong Growth and Profits in 2010 Fourth Quarter
9. China Pharma Holdings, Inc. Reports Full Year 2010 Financial Results
10. Sequenom Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11. Assured Pharmacy Reports Same Store Sales for the Month of December 2010
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015   Nuance Communications, Inc. ... National Decision Support Company (NDSC) today jointly announced ... collaboration capabilities that utilize the American College of Radiology,s ... provider organizations to comply with current and emerging ... --> By combining clinical decision support, ...
(Date:11/30/2015)... 2015  Hanger, Inc. (NYSE: HGR ) (the ... terms of its previously announced consent solicitation (as amended ... aggregate principal amount 7⅛% Senior Notes due 2018 (the ... fees payable pursuant to the Consent Solicitation, (ii) the ... the expiration date of the Consent Solicitation.    ...
(Date:11/30/2015)... LONDON and BOSTON , ... to research and develop potential new medicines directed at ... multiple therapeutic areas. --> PFE ) to ... to 10 G protein-coupled receptor (GPCR) targets across multiple ... clinical-stage GPCR structure-guided drug discovery and development company and ...
Breaking Medicine Technology:
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... healthcare professionals worldwide today released the results of a survey of educational needs ... and Africa found a growing global demand for high quality online and face-to-face ...
(Date:11/30/2015)... , ... November 30, 2015 ... ... to announce their strategic partnership at the Radiological Society of North America ... Winscribe, global providers of cutting-edge dictation and speech-enabled documentation software, announced their ...
(Date:11/30/2015)... ... November 30, 2015 , ... Several significant ... coding changes are likely to include new codes for spine and hip X-rays, ... understand the effects of code changes in musculoskeletal, radiology and nervous system sections ...
(Date:11/30/2015)... TX (PRWEB) , ... November 30, 2015 , ... Bayco Products, Inc today announced the ... $11.95 each. Available in a choice of three different colors; red ( NSP-1632 ), yellow ... each run up to 18 hours in constant-on mode, or 27 hours in blinking strobe ...
(Date:11/29/2015)... ... November 30, 2015 , ... Gift ideas ... Sublime Beauty NATURALS®. All products are available on Amazon or its webstore. , ... facial serums and USDA Certified Organic Sesame Oil for Oil Pulling," says Kathy ...
Breaking Medicine News(10 mins):